InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,598.80
(
1.03%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.40
(
0.32%
)
Bitcoin
63,381.84
(
-0.96%
)
Post# of 689349
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Lykiri

Send PM Follow Ignore
Followers 113
Posts 1859
Boards Moderated 0
Alias Born 11/22/2017

Lykiri

Re: Kaizenman post# 525422

Thursday, 10/27/2022 6:20:59 PM

Thursday, October 27, 2022 6:20:59 PM

Post# of 689349

"Rational combination strategies and treatment approaches are needed to tackle the problem of brain cancer treatment-induced resistance over time "


Kaizeman,

Immunotherapy resistance:
- DC vaccine/poly-ICLC + anti-PD1 + CSF1-Ri
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News
InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news
Only $200 per official company press release!